Stockreport

New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF confirm its effectiveness and tolerability in a real-world patient population, which on average had severe, chronic, treatment-resistant depression (TRD). The study of [Read more]